NUCRYST Pharmaceuticals to Release Third Quarter 2008 Financial Results on Thursday, November 6, 2008



    WAKEFIELD, MA, Oct. 24 /CNW/ - NUCRYST Pharmaceuticals Corp. (NASDAQ:  
NCST; TSX: NCS), a developer and manufacturer of medical products that fight
infection and inflammation, announced plans to release its financial results
for the third quarter 2008 on Thursday, November 6, 2008.
    The company will host a conference call at 9:00 AM ET on Friday, November
7, 2008 to discuss the financial results for the quarter.

    
    Conference call details:

    Date:     Friday, November 7, 2008
    Time:     9:00 AM ET
    Dial-in:  866-578-5747 (U.S.)
              617-213-8054 (International)
    Passcode: 50533222
    Web cast: http://www.nucryst.com (Investor Relations section)

    An audio replay of the call will be available for 7 days:
    Access:   888-286-8010 (U.S.)
              617-801-6888 (International)
              Replay Passcode: 74057266
    

    In addition to the standard disclosure over wire services, a news release
and financial statements will be posted on the NUCRYST website.

    About NUCRYST Pharmaceuticals

    NUCRYST Pharmaceuticals Corp. (NASDAQ:   NCST; TSX: NCS) develops,
manufactures and commercializes medical products that fight infection and
inflammation using SILCRYST(TM), its patented atomically disordered
nanocrystalline silver technology. NUCRYST licensed world-wide rights for
SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets
these products in over 30 countries under their Acticoat(TM) trademark.
NUCRYST is also developing pharmaceutical products to address medical
conditions that are characterized by pain, infection and inflammation. The
Company has developed its proprietary nanocrystalline silver in a powder form,
referred to as NPI 32101 for use in medical devices and as an active
pharmaceutical ingredient.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

    %SEDAR: 00023031E




For further information:

For further information: David B. Holtz, Vice President and Chief
Financial Officer, NUCRYST Pharmaceuticals Corp., (781) 224-1444,
info@nucryst.com; Fern Lazar, Lazar Partners, (212) 867-1762

Organization Profile

NUCRYST PHARMACEUTICALS CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890